NASDAQ: CLRB - Cellectar Biosciences, Inc.

Yield per half year: -41.02%
Sector: Healthcare

Share chart Cellectar Biosciences, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer.

More details
Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r pediatric patients with head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

EBITDA -0.0142
EV/EBITDA -0.532
IPO date 2005-11-10
ISIN US15117F8077
Industry Biotechnology
P/BV 1.95
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.cellectar.com
Цена ао 3.85
Число акций ао 0.01222 млрд
Change price per day: +1.85% (2.16)
Change price per week: +7.84% (2.04)
Change price per month: +4.76% (2.1)
Change price per 3 month: -11.29% (2.48)
Change price per half year: -41.02% (3.73)
Change price per year: -24.14% (2.9)
Change price per 3 year: +125.06% (0.9775)
Change price per 5 year: +3.77% (2.12)
Change price per 10 year: 0% (2.2)
Change price per year to date: -20.58% (2.77)
All parameters

Underestimation

Title Value Grade
P/S 0 0
P/BV -23.25 0
P/E 0 0
EV/EBITDA -0.5809 0
Total: 2.5

Efficiency

Title Value Grade
ROA, % -314.55 0
ROE, % 2801.05 10
Total: 3.33

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0.5857

Debt

Title Value Grade
Debt/EBITDA -0.0143 10
Total: 10

Growth impulse

Title Value Grade
Yield Revenue, % -187.41 0
Yield Ebitda, % 173.02 10
Yield EPS, % -82.81 0
Total: 6
More

Institutions Volume Share, %
Nantahala Capital Management, LLC 2701156 8.37
Rosalind Advisors, Inc. 2005658 6.22
AIGH Capital Management LLC 1915220 5.94
Adar1 Capital Management, LLC 1378082 4.27
Worth Venture Partners, LLC 693909 2.15
Vanguard Group Inc 482890 1.5
Acuta Capital Partners LLC 477500 1.48
Citadel Advisors Llc 69007 0.21
Geode Capital Management, LLC 68870 0.21
Blackrock Inc. 57042 0.18

ETF Share, % Profitability for 1 year, % Dividends, %
iShares Micro-Cap ETF 0.01881 11.903735012508 1.54048



Head Job title Payment Year of birth
Mr. James V. Caruso President, CEO & Director 1.14M 1959 (65 years)
Mr. Chad J. Kolean CPA VP, CFO & Secretary 711.23k 1964 (60 years)
Mr. Jarrod Longcor Chief Operating Officer 854.24k 1973 (51 year)
Mr. Darrell Shane Lea Chief Commercial Officer N/A 1974 (50 years)
Dr. Andrei Shustov M.D. Senior Vice President of Medical N/A 1972 (52 years)

Address: United States, Florham Park. NJ, 100 Campus Drive - open in Google maps, open in Yandex maps
Website: https://www.cellectar.com